Home > Insider Trading > Filing (0001209191-17-027983)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	Pharmaceutical Preparations (2834)	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
816284	Celgene Corp /De/	86 Morris Avenue Summit NJ 07901	No	No	Yes	No
1577650	Celgene European Investment Co Llc	86 Morris Avenue Summit NJ 07901	No	No	Yes	No
1581774	Celgene Alpine Investment Co., Llc	86 Morris Avenue Summit NJ 07901	No	No	Yes	No
1661486	Celgene Switzerland Llc	Aon House 30 Woodbourne Avenue Pembroke D0 HM 08	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-04-24	624,575	$49.50	1,856,353	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,010,926	Direct

Footnotes

Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC ("Celgene Switzerland"), 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC ("Celgene Alpine"), each a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene and Celgene European Investment Company LLC, a wholly owned subsidiary of Celgene ("CEICO"), disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. The remaining 523,445 shares are owned directly by Celgene. CEICO, Celgene Switzerland and Celgene Alpine disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
These shares are owned directly by CEICO, and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene, Celgene Switzerland and Celgene Alpine disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.